Early Disease-Modifying Treatments for Presymptomatic Multiple Sclerosis

被引:0
作者
Zeydan, Burcu [1 ,2 ]
Azevedo, Christina J. [3 ]
Makhani, Naila [4 ,5 ]
Cohen, Mikael [6 ]
Tutuncu, Melih [7 ]
Thouvenot, Eric [8 ,9 ]
Siva, Aksel [7 ]
Okuda, Darin T. [10 ,11 ]
Kantarci, Orhun H. [2 ]
Lebrun-Frenay, Christine [6 ]
机构
[1] Mayo Clin, Dept Radiol, 200 First St SW, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA
[3] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA
[4] Yale Sch Med, Dept Pediat, New Haven, CT USA
[5] Yale Sch Med, Dept Neurol, New Haven, CT USA
[6] Cote Azur Univ, Pasteur 2 Univ Hosp, Dept Neurol, MS Clin Nice,UR2CA URRIS, Nice, France
[7] Istanbul Univ, Cerrahpasa Sch Med, Dept Neurol, Istanbul, Turkiye
[8] Univ Montpellier, Nimes Univ Hosp Ctr, Dept Neurol, Nimes, France
[9] Montpellier Univ, IGF, CNRS, INSERM, Montpellier, France
[10] Univ Texas Southwestern Med Ctr, Neuroinnovat Program, Dallas, TX USA
[11] Univ Texas Southwestern Med Ctr, Multiple Sclerosis & Neuroimmunol Imaging Program, Dallas, TX USA
基金
美国国家卫生研究院;
关键词
RADIOLOGICALLY ISOLATED SYNDROME; INTRAMUSCULAR INTERFERON BETA-1A; 1ST DEMYELINATING EVENT; CLINICALLY DEFINITE; FOLLOW-UP; CONVERSION; ASSOCIATION; DIAGNOSIS; REVISIONS; PHASE;
D O I
10.1007/s40263-024-01117-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Radiologically isolated syndrome (RIS) is the earliest stage in the disease continuum of multiple sclerosis (MS). RIS is discovered incidentally in individuals who are asymptomatic but have typical lesions in the brain and/or spinal cord suggestive of demyelination. The 2009 and revised 2023 RIS criteria were developed for diagnosis. Presymptomatic individuals who fulfill the 2009 RIS criteria by having 3-4 of 4 dissemination in space McDonald 2005 MS criteria are still diagnosed with RIS using the revised 2023 RIS criteria. In presymptomatic individuals who do not fulfill the 2009 RIS criteria, the revised 2023 RIS criteria target to secure an accurate and timely diagnosis: In addition to (a) having one lesion in two of four locations (periventricular, juxtacortical/cortical, infratentorial, spinal cord), (b) two of three features (spinal cord lesion, cerebrospinal fluid (CSF)-restricted oligoclonal bands, and new T2 or gadolinium-enhancing lesion) should be fulfilled. Among laboratory biomarkers, CSF kappa-free light chain can also increase diagnostic accuracy. Once the diagnosis is confirmed, the established risk factors, including demographics, imaging, and laboratory biomarkers, should be evaluated for symptomatic MS transition and prognosis. Younger age, male sex, increased neurofilament-light chain, CSF abnormality, and the presence of infratentorial, spinal cord, or gadolinium-enhancing lesions on imaging are the main risk factors for transition to symptomatic MS. Two randomized clinical trials showed significant efficacy of disease-modifying treatments in delaying or preventing the development of the first clinical event in RIS. However, because some individuals remain as RIS, it is crucial to identify the individuals with a higher number of risk factors to optimize disease outcomes by early intervention while minimizing adverse events. Discussing each RIS case with an expert MS team is recommended because there is still a lack of clinical guidelines to improve care, counseling, and surveillance.
引用
收藏
页码:973 / 983
页数:11
相关论文
共 50 条
  • [21] Association of Disease-Modifying Treatment With Outcome in Patients With Relapsing Multiple Sclerosis and Isolated MRI Activity
    Bsteh, Gabriel
    Aicher, Marie L.
    Walde, Janette F.
    Krajnc, Nik
    Haider, Lukas
    Traxler, Gerhard
    Gradl, Christiane
    Salmen, Anke
    Riedl, Katharina
    Poskaite, Paulina
    Leyendecker, Philipp
    Altmann, Patrick
    Auer, Michael
    Berek, Klaus
    Di Pauli, Franziska
    Kornek, Barbara
    Leutmezer, Fritz
    Rommer, Paulus S.
    Zulehner, Gudrun
    Zrzavy, Tobias
    Deisenhammer, Florian
    Chan, Andrew
    Berger, Thomas
    Hoepner, Robert
    Hammer, Helly
    Hegen, Harald
    NEUROLOGY, 2024, 103 (06)
  • [22] Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis
    Amato, Maria Pia
    Fonderico, Mattia
    Portaccio, Emilio
    Pasto, Luisa
    Razzolini, Lorenzo
    Prestipino, Elio
    Bellinvia, Angelo
    Tudisco, Laura
    Fratangelo, Roberto
    Comi, Giancarlo
    Patti, Francesco
    De Luca, Giovanna
    Morra, Vincenzo Brescia
    Cocco, Eleonora
    Pozzilli, Carlo
    Sola, Patrizia
    Bergamaschi, Roberto
    Salemi, Giuseppe
    Inglese, Matilde
    Millefiorini, Enrico
    Galgani, Simonetta
    Zaffaroni, Mauro
    Ghezzi, Angelo
    Salvetti, Marco
    Lus, Giacomo
    Florio, Ciro
    Totaro, Rocco
    Granella, Franco
    Vianello, Marika
    Gatto, Maurizia
    Di Battista, Giancarlo
    Aguglia, Umberto
    Logullo, Francesco Ottavio
    Simone, Marta
    Lucisano, Giuseppe
    Iaffaldano, Pietro
    Trojano, Maria
    BRAIN, 2020, 143 : 3013 - 3024
  • [23] The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
    Pardo, Gabriel
    Jones, David E.
    JOURNAL OF NEUROLOGY, 2017, 264 (12) : 2351 - 2374
  • [24] Safety and Monitoring of the Treatment with Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS)
    Stamatellos, Vasileios-Periklis
    Papazisis, Georgios
    CURRENT REVIEWS IN CLINICAL AND EXPERIMENTAL PHARMACOLOGY, 2023, 18 (01) : 39 - 50
  • [25] Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors
    Bsteh, Gabriel
    Feige, Julia
    Ehling, Rainer
    Auer, Michael
    Hegen, Harald
    Di Pauli, Franziska
    Deisenhammer, Florian
    Reindl, Markus
    Berger, Thomas
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (09) : 1241 - 1248
  • [26] Effect of disease-modifying treatment on spinal cord lesion formation in multiple sclerosis: A retrospective observational study
    Kreiter, Daniel
    Spee, Romy
    Merry, Audrey
    Hupperts, Raymond
    Gerlach, Oliver
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 79
  • [27] Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
    Wiendl, Heinz
    Gold, Ralf
    Berger, Thomas
    Derfuss, Tobias
    Linker, Ralf
    Maurer, Mathias
    Aktas, Orhan
    Baum, Karl
    Berghoff, Martin
    Bittner, Stefan
    Chan, Andrew
    Czaplinski, Adam
    Deisenhammer, Florian
    Di Pauli, Franziska
    Du Pasquier, Renaud
    Enzinger, Christian
    Fertl, Elisabeth
    Gass, Achim
    Gehring, Klaus
    Gobbi, Claudio
    Goebels, Norbert
    Guger, Michael
    Haghikia, Aiden
    Hartung, Hans-Peter
    Heidenreich, Fedor
    Hoffmann, Olaf
    Kallmann, Boris
    Kleinschnitz, Christoph
    Klotz, Luisa
    Leussink, Verena I.
    Leutmezer, Fritz
    Limmroth, Volker
    Lunemann, Jan D.
    Lutterotti, Andreas
    Meuth, Sven G.
    Meyding-Lamade, Uta
    Platten, Michael
    Rieckmann, Peter
    Schmidt, Stephan
    Tumani, Hayrettin
    Weber, Frank
    Weber, Martin S.
    Zettl, Uwe K.
    Ziemssen, Tjalf
    Zipp, Frauke
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [28] Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies
    Smith, Tyler Ellis
    Kister, Ilya
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2021, 21 (07)
  • [29] Disease-Modifying Agents in the Treatment of Multiple Sclerosis: A Review of Long-Term Outcomes
    Katrych, Oleksandra
    Simone, Tessa M.
    Azad, Shara
    Mousa, Shaker A.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2009, 8 (06) : 512 - 519
  • [30] Disease-modifying strategies: Targeting protein kinases in multiple sclerosis and other autoimmune disorders
    Konen, Franz Felix
    Moehn, Nora
    Witte, Torsten
    Schefzyk, Matthias
    Wiestler, Miriam
    Lovric, Svjetlana
    Hufendiek, Karsten
    Jendretzky, Konstantin Fritz
    Gingele, Stefan
    Schwenkenbecher, Philipp
    Suehs, Kurt-Wolfram
    Friese, Manuel A.
    Klotz, Luisa
    Pul, Refik
    Pawlitzki, Marc
    Hagin, David
    Kleinschnitz, Christoph
    Meuth, Sven G.
    Skripuletz, Thomas
    AUTOIMMUNITY REVIEWS, 2025, 24 (04)